Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
ValiRx added that the data had confirmed there were no significant adverse trends across liver or kidney function as a result of the VAL201 treatment, as well as “no impact on cardiac rhythm”.
Information from the clinical evaluation had also shown that ValiRx was addressing the protocol's primary and secondary endpoints - as well as all the exploratory tertiary endpoints.
The company entered the final stages of the Phase I/II trial in October, when it was given permission by UK regulators to up the dose it gave to patients after early feedback showed the drug was safe and well-tolerated.
Dr Satu Vainikka, chief executive of ValiRx, said the treatment was having “having a positive and desired effect on prostate cancer patients' disease markers”.
He added that the latest data showed “the more a patient takes VAL201, the more a patient's PSA will decrease".
just don't understand that when these people know where the program is and how long it may take to take it to next phase then why don't they raise funds for a full year or so when the SP is high. Also, every time they raise funds, a fee is applicable.